After the July 2026 FDA decision, at-home Leqembi Iqlik and clinic IV infusions are both initiation options for mild cognitive impairment due to Alzheimer's. Leqembi Iqlik, a subcutaneous form of lecanemab-irmb, uses two weekly autoinjector shots, while IV lecanemab requires clinic infusions.
Mild cognitive impairment here means early memory and thinking changes from Alzheimer's, not normal aging. According to the Eisai/Biogen announcement, FDA approved the 500-mg once-weekly initiation dose on July 13, 2026 the Eisai/Biogen approval notice. Home dosing changes the setting, not the need for testing and MRI follow-up.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Alzheimers — Use this primary source to verify the official guidance.
- Register through Amazonaws’s official page — Use this page to review requirements and register directly.
Table of Contents
- What changed for starting treatment?
- Who can start at home?
- What training and safety checks remain?
- How do access and coverage differ?
What changed for starting treatment?
Before July 2026, subcutaneous dosing was maintenance only. Drugs.com approval history records FDA allowed 360-mg weekly shots only after 18 months of IV treatment. The July action made subcutaneous dosing an initiation path.
Managed Healthcare Executive reports home initiation launched August 24, 2026. A patient or care partner gives two 250-mg shots after provider training. Each injection takes about 15 seconds.
Who can start at home?
CMS limits coverage to early symptomatic disease. The CMS determination summary via Clover Health policy describes mild cognitive impairment due to Alzheimer's plus mild dementia, with confirmed amyloid pathology and required monitoring.
Home initiation does not widen that group. Check these items before asking about home start: If any item is missing, either path pauses until it is met. Bring test results and monitoring records to the eligibility visit.
- early symptomatic diagnosis on record
- amyloid pathology confirmed
- enrollment in required monitoring
- ability to complete training with a care partner if needed
What training and safety checks remain?
Managed Healthcare Executive reports patients or care partners can inject at home after health-care-provider training. Each shot takes about 15 seconds. Ask the prescribing clinic to document who was trained and on which steps. Lecanemab retains a boxed warning for amyloid-related imaging abnormalities, or ARIA, which means abnormal MRI findings.
According to the FDA prescribing information summary, baseline and follow-up MRIs plus ApoE ε4 testing are required the FDA prescribing information summary. The same summary reports ARIA in about 21% overall and 45% in ApoE4 homozygotes. Keep MRI appointments even when injections feel routine. Report headache, confusion, dizziness, vision changes, or weakness promptly.
How do access and coverage differ?
Medicare traditionally covers IV lecanemab under Part B only through Coverage with Evidence Development. The CMS explainer requires a CMS-approved registry with baseline and 6-month follow-up data. According to Managed Healthcare Executive, wholesale cost is $385 per autoinjector, or $770 per week the Managed Healthcare Executive launch report.
The same report lists a $2,100 Part D annual cap plus monthly smoothing. It also lists $0 commercial copay up to $10,000 per year and free drug for eligible uninsured patients. Bring amyloid results, ApoE results, MRI dates, registry papers, and the Part D formulary printout to the visit. Ask which pharmacy will bill Part D and who schedules follow-up MRIs.
You Might Also Like
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: A Source-Checked Briefing for People With Mild Cognitive Impairment
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Access, Coverage, and Training Questions for Adult Children
- Building Learning a New Skill Into a Realistic Dementia Prevention Routine With Mild Cognitive Impairment
